How this week’s cord blood breakthrough could help your child

In one of the most exciting breakthroughs for umbilical cord blood to date, Doctors at Duke University in North Carolina have received permission to offer cord blood stem cell therapy for a range of acquired neurological disorders including cerebral palsy and autism.

Following the success of a series of trials at the leading medical university using cord blood to treat cerebral palsy, this expanded access trial will enable more children than ever before to receive a treatment proven to improve day to day functioning.

“The registration of this clinical trial is a watershed moment, opening the door for many children who are afflicted with an acquired neurological disorder to travel to Duke University for cord blood therapy, provided they have a sufficiently matching cord blood unit in a family bank.” (Cell Trials Data)

For the first time, children suffering not only with cerebral palsy but with any acquired neurological disorder will be eligible for treatment, provided their umbilical cord blood, or a sibling’s cord blood has been privately stored.

Conditions to be treated under this breakthrough trial include:

Autism Spectrum Disorder

Cerebral Palsy

Hydrocephalus

Apraxia

Apraxia of Speech

Hypoxia Ischemia

Cerebral Drowning

Anoxia

Stroke and other brain injuries will also be treated, significantly increasing the number of conditions considered treatable with cord blood stem cells.

Cord blood therapy is set to revolutionise medicine, but with each stem cell transplant costing as much as £300,000, families are not always able to access the care their child needs.

CellPlan unlocks the potential of stored cord blood. If your baby or a matching family member is diagnosed with a condition that can be treated with umbilical cord blood, CellPlan can provide worldwide medical support and funding treatment, transport and accommodation.

Applying for CellPlan insurance is easy. You can request a quote, brochure, or call back here.